vs
Side-by-side financial comparison of BALCHEM CORP (BCPC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
BALCHEM CORP is the larger business by last-quarter revenue ($270.7M vs $177.4M, roughly 1.5× Pacira BioSciences, Inc.). BALCHEM CORP runs the higher net margin — 14.9% vs 1.6%, a 13.2% gap on every dollar of revenue. On growth, BALCHEM CORP posted the faster year-over-year revenue change (8.1% vs 5.0%). Over the past eight quarters, BALCHEM CORP's revenue compounded faster (7.5% CAGR vs -0.2%).
Balchem Corp is a global specialty chemicals and nutritional ingredients provider that develops, manufactures and distributes application-specific products for human nutrition, animal health, pharmaceutical and industrial end markets, serving customers across North America, Europe and Asia Pacific.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
BCPC vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $270.7M | $177.4M |
| Net Profit | $40.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 20.5% | 3.9% |
| Net Margin | 14.9% | 1.6% |
| Revenue YoY | 8.1% | 5.0% |
| Net Profit YoY | 8.7% | — |
| EPS (diluted) | $1.25 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $270.7M | $177.4M | ||
| Q4 25 | $263.6M | $196.9M | ||
| Q3 25 | $267.6M | $179.5M | ||
| Q2 25 | $255.5M | $181.1M | ||
| Q1 25 | $250.5M | $168.9M | ||
| Q4 24 | $240.0M | $187.3M | ||
| Q3 24 | $239.9M | $168.6M | ||
| Q2 24 | $234.1M | $178.0M |
| Q1 26 | $40.3M | $2.9M | ||
| Q4 25 | $39.2M | — | ||
| Q3 25 | $40.3M | $5.4M | ||
| Q2 25 | $38.3M | $-4.8M | ||
| Q1 25 | $37.1M | $4.8M | ||
| Q4 24 | $33.6M | — | ||
| Q3 24 | $33.8M | $-143.5M | ||
| Q2 24 | $32.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 35.6% | 79.5% | ||
| Q3 25 | 35.7% | 80.9% | ||
| Q2 25 | 36.4% | 77.4% | ||
| Q1 25 | 35.2% | 79.7% | ||
| Q4 24 | 36.0% | 78.7% | ||
| Q3 24 | 35.6% | 76.9% | ||
| Q2 24 | 35.5% | 75.1% |
| Q1 26 | 20.5% | 3.9% | ||
| Q4 25 | 19.8% | 1.2% | ||
| Q3 25 | 20.4% | 3.5% | ||
| Q2 25 | 20.1% | 4.7% | ||
| Q1 25 | 20.4% | 1.2% | ||
| Q4 24 | 19.8% | 13.2% | ||
| Q3 24 | 20.0% | -82.8% | ||
| Q2 24 | 19.6% | 15.9% |
| Q1 26 | 14.9% | 1.6% | ||
| Q4 25 | 14.9% | — | ||
| Q3 25 | 15.1% | 3.0% | ||
| Q2 25 | 15.0% | -2.7% | ||
| Q1 25 | 14.8% | 2.8% | ||
| Q4 24 | 14.0% | — | ||
| Q3 24 | 14.1% | -85.1% | ||
| Q2 24 | 13.7% | 10.6% |
| Q1 26 | $1.25 | $0.07 | ||
| Q4 25 | $1.21 | $0.05 | ||
| Q3 25 | $1.24 | $0.12 | ||
| Q2 25 | $1.17 | $-0.11 | ||
| Q1 25 | $1.13 | $0.10 | ||
| Q4 24 | $1.03 | $0.38 | ||
| Q3 24 | $1.03 | $-3.11 | ||
| Q2 24 | $0.98 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $72.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $653.9M |
| Total Assets | $1.7B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $72.9M | $144.3M | ||
| Q4 25 | $74.6M | $238.4M | ||
| Q3 25 | $65.1M | $246.3M | ||
| Q2 25 | $65.4M | $445.9M | ||
| Q1 25 | $49.9M | $493.6M | ||
| Q4 24 | $49.5M | $484.6M | ||
| Q3 24 | $73.7M | $453.8M | ||
| Q2 24 | $63.7M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $1.3B | $653.9M | ||
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.3B | $727.2M | ||
| Q2 25 | $1.3B | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | $1.1B | $778.3M | ||
| Q3 24 | $1.2B | $749.6M | ||
| Q2 24 | $1.1B | $879.3M |
| Q1 26 | $1.7B | $1.2B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.7B | $1.3B | ||
| Q2 25 | $1.7B | $1.5B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.6B | ||
| Q3 24 | $1.6B | $1.5B | ||
| Q2 24 | $1.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $40.1M | — |
| Free Cash FlowOCF − Capex | $33.8M | — |
| FCF MarginFCF / Revenue | 12.5% | — |
| Capex IntensityCapex / Revenue | 2.3% | — |
| Cash ConversionOCF / Net Profit | 0.99× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $40.1M | — | ||
| Q4 25 | $67.3M | $43.7M | ||
| Q3 25 | $65.6M | $60.8M | ||
| Q2 25 | $47.3M | $12.0M | ||
| Q1 25 | $36.5M | $35.5M | ||
| Q4 24 | $52.3M | $33.1M | ||
| Q3 24 | $51.3M | $53.9M | ||
| Q2 24 | $45.0M | $53.2M |
| Q1 26 | $33.8M | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $51.6M |
| Q1 26 | 12.5% | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 29.0% |
| Q1 26 | 2.3% | — | ||
| Q4 25 | — | 0.1% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 5.1% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.9% |
| Q1 26 | 0.99× | — | ||
| Q4 25 | 1.72× | — | ||
| Q3 25 | 1.63× | 11.20× | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 0.98× | 7.37× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | 1.40× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCPC
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
